Addition of Rubidomycin to Induction Treatment with Vincristine, Prednisone, and l-Asparaginase in Standard-Risk Childhood Acute Lymphocytic Leukemia (Study ALL V): A Report on Behalf of the Dutch Childhood Leukemia Study Group

1987 ◽  
pp. 444-447 ◽  
Author(s):  
A. van der Does-van den Berg ◽  
E. R. van Wering ◽  
J. de Koning ◽  
J. A. Rammeloo ◽  
G. Solbu ◽  
...  
Keyword(s):  
Acute Lymphocytic Leukemia ◽  
Childhood Leukemia ◽  
Lymphocytic Leukemia ◽  
Induction Treatment ◽  
Study Group ◽  
Standard Risk

Addition of rubidomycine to induction treatment with vincristine, prednison and L-asparaginase in standard risk childhood acute lymphocytic leukemia

1986 ◽  
Vol 10 (1) ◽  
pp. 112 ◽  
Author(s):  
A.v.d. Does-v.d. Berg ◽  
E.R.v. Wering ◽  
J.d. Koning ◽  
J.A. Rammeloo ◽  
G. Solbu ◽  
...  
Keyword(s):  
Acute Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Induction Treatment ◽  
Standard Risk

scholarly journals Comparative Analysis of Systemic and Tumor Microenvironment Proteomes From Children With B-Cell Acute Lymphocytic Leukemia at Diagnosis and After Induction Treatment

2020 ◽  
Vol 10 ◽  
Author(s):  
Geise Ellen Broto ◽  
Stephany Corrêa ◽  
Fausto Celso Trigo ◽  
Everton Cruz dos Santos ◽  
Fernanda Tomiotto-Pelissier ◽  
...  
Keyword(s):  
Transcription Factor ◽  
B Cell ◽  
Acute Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Induction Treatment ◽  
Induction Phase ◽  
Label Free ◽  
Childhood Diseases ◽  
Coagulation Proteins ◽  
Ifn Γ

Among the childhood diseases, B-cell acute lymphocytic leukemia (B-ALL) is the most frequent type of cancer. Despite recent advances concerning disease treatment, cytotoxic chemotherapy remains the first line of treatment in several countries, and the modifications induced by such drugs in the organism are still poorly understood. In this context, the present study provided a comparative high-throughput proteomic analysis of the cumulative changes induced by chemotherapeutic drugs used in the induction phase of B-ALL treatment in both peripheral blood (PB) and bone marrow compartment (BM) samples. To reach this goal, PB and BM plasma samples were comparatively analyzed by using label-free proteomics at two endpoints: at diagnosis (D0) and the end of the cumulative induction phase treatment (D28). Proteomic data was available via ProteomeXchange with identifier PXD021584. The resulting differentially expressed proteins were explored by bioinformatics approaches aiming to identify the main gene ontology processes, pathways, and transcription factors altered by chemotherapy, as well as to understand B-ALL biology in each compartment at D0. At D0, PB was characterized as a pro-inflammatory environment, with the involvement of several downregulated coagulation proteins as KNG, plasmin, and plasminogen. D28 was characterized predominantly by immune response-related processes and the super expression of the transcription factor IRF3 and transthyretin. RUNX1 was pointed out as a common transcription factor found in both D0 and D28. We chose to validate the proteins transthyretin and interferon-gamma (IFN-γ) by commercial kits and expressed the results as PB/BM ratios. Transthyretin ratio was augmented after induction chemotherapy, while IFN-γ was reduced at the end of the treatment. Considering that most of these proteins were not yet described in B-ALL literature, these findings added to understanding disease biology at diagnosis and highlighted a possible role for transthyretin and IFN-γ as mechanisms related to disease resolution.

Prolonged second remissions in childhood acute lymphocytic leukemia: A report from the childrens cancer study group

1983 ◽  
Vol 11 (1) ◽  
pp. 1-7 ◽  
Author(s):  
E. Baum ◽  
J. Nachman ◽  
N. Ramsay ◽  
B. Weetman ◽  
R. Neerhout ◽  
...  
Keyword(s):  
Acute Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Study Group ◽  
Cancer Study ◽  
Cancer Study Group

HOPES FOR TOMORROW VERSUS REALITIES OF TODAY: THERAPY AND PROGNOSIS IN ACUTE LYMPHOCYTIC LEUKEMIA OF CHILDHOOD

PEDIATRICS ◽  
1970 ◽  
Vol 45 (2) ◽  
pp. 191-193
Author(s):  
James F. Holland
Keyword(s):  
Acute Leukemia ◽  
Acute Lymphocytic Leukemia ◽  
Childhood Leukemia ◽  
Lymphocytic Leukemia ◽  
Current Therapy ◽  
Therapeutic Approaches ◽  
Institutional Level ◽  
Clinical Investigations ◽  
Group B ◽  
Leukemia Group

The inability of Drs. Stein, Ablin, Kushner and Zoger, in their Letter to the Editor1, to "see what good can come of exaggerating the effectiveness of current therapy" for childhood leukemia is not surprising. They imply that others have such distorted vision that they see castles where only hovels stand. The implication of Dr. Stein and his colleagues, were it true, would be damning. I believe that faulty logic, poor data, sketchy analysis, and embellished accounts in the popular press over which the interviewed exercises no editorial control led these correspondents to improper conclusions. In the design of clinical investigations to explore potentially improved therapeutic approaches to acute lymphocytic leukemia, the Acute Leukemia Group B has structured from two to five regimens into concurrent comparisons on a multi-institutional level.

scholarly journals Comparison of Intermediate-Dose Methotrexate with Cranial Irradiation for the Post-Induction Treatment of Acute Lymphocytic Leukemia in Children

1983 ◽  
Vol 308 (9) ◽  
pp. 477-484 ◽  
Author(s):  
Arnold I. Freeman ◽  
Vivian Weinberg ◽  
Martin L. Brecher ◽  
Barbara Jones ◽  
Arvin S. Glicksman ◽  
...  
Keyword(s):  
Acute Lymphocytic Leukemia ◽  
Cranial Irradiation ◽  
Lymphocytic Leukemia ◽  
Induction Treatment ◽  
Post Induction ◽  
Dose Methotrexate ◽  
Leukemia In Children ◽  
Intermediate Dose

Brain sarcoma of meningeal origin after cranial irradiation in childhood acute lymphocytic leukemia

1984 ◽  
Vol 61 (4) ◽  
pp. 772-776 ◽  
Author(s):  
Pascal Tiberin ◽  
Esther Maor ◽  
Rina Zaizov ◽  
Ian J. Cohen ◽  
Menachem Hirsch ◽  
...  
Keyword(s):  
Acute Lymphocytic Leukemia ◽  
Childhood Leukemia ◽  
Multimodality Treatment ◽  
Cranial Irradiation ◽  
Lymphocytic Leukemia ◽  
Whole Brain Irradiation ◽  
Content Type ◽  
Brain Irradiation ◽  
Low Dosage

✓ The authors report their experience with an unusual case of intracerebral sarcoma of meningeal cell origin in an 8½-year-old girl. This tumor occurred 6½ years after cranial irradiation at relatively low dosage (2200 rads) had been delivered to the head in the course of a multimodality treatment for acute lymphocytic leukemia. The tumor recurred approximately 10 months after the first surgical intervention. Macroscopic total excision of the recurrent growth followed by whole-brain irradiation (4500 rads) failed to eradicate it completely and local recurrence prompted reoperation 18 months later. This complication of treatment in long-term childhood leukemia survivors is briefly discussed, as well as the pathology of meningeal sarcomas.

Abstract 271: Rising rates of acute lymphocytic leukemia in Hispanic children: A review of trends in childhood leukemia incidence from 1973-2010

2014 ◽  
Author(s):  
Jessica Barrington-Trimis ◽  
Myles Cockburn ◽  
Catherine Metayer ◽  
W. James Gauderman ◽  
Joseph Wiemels ◽  
...  
Keyword(s):  
Acute Lymphocytic Leukemia ◽  
Childhood Leukemia ◽  
Lymphocytic Leukemia ◽  
Hispanic Children
Sign in / Sign up

Export Citation Format

Share Document